# A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer

> **NCT06533644** · PHASE2 · RECRUITING · sponsor: **Syncromune, Inc.** · enrollment: 91 (estimated)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer

## Interventions

- **PROCEDURE:** Partial Oncolysis
- **DRUG:** SV-102

## Key facts

- **NCT ID:** NCT06533644
- **Lead sponsor:** Syncromune, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-29
- **Primary completion:** 2028-04-14
- **Final completion:** 2028-04-14
- **Target enrollment:** 91 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06533644

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06533644, "A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06533644. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*